These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38677063)

  • 41. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
    Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
    Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccine vial monitor availability and use in low- and middle-income countries: A systematic review.
    Eriksson P; Gessner BD; Jaillard P; Morgan C; Le Gargasson JB
    Vaccine; 2017 Apr; 35(17):2155-2161. PubMed ID: 28364924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Access to cardiovascular medicines in low- and middle-income countries: a mini review.
    Harrison MA; Marfo AFA; Annan A; Ankrah DNA
    Glob Health Res Policy; 2023 May; 8(1):17. PubMed ID: 37221559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apropos "New vaccines for developing countries: will it be feast or famine"?
    Arya SC; Agarwal N
    Am J Law Med; 2009; 35(4):691. PubMed ID: 20196288
    [No Abstract]   [Full Text] [Related]  

  • 46. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Value-based tiered pricing for universal health coverage: an idea worth revisiting.
    Chalkidou K; Claxton K; Silverman R; Yadav P
    Gates Open Res; 2020; 4():16. PubMed ID: 32185365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The challenge of changing the inactivated poliomyelitis vaccine in Latin America: declaration of the Latin American Society of Pediatric Infectious Diseases (SLIPE).
    Falleiros-Arlant LH; Avila-Agüero ML; Brea del Castillo J; Mariño C
    Rev Chilena Infectol; 2014 Oct; 31(5):590-603. PubMed ID: 25491459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
    Obeng-Kusi M; Erstad B; Roe DJ; Abraham I
    J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Country and regional variations in purchase prices for essential cancer medications.
    Cuomo RE; Seidman RL; Mackey TK
    BMC Cancer; 2017 Aug; 17(1):566. PubMed ID: 28836947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Casting off vaccine supply charity -- the pace quickens. CVI goal: quality vaccines for all children.
    CVI Forum; 1995 Oct; (10):9-13. PubMed ID: 12290725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EPI Revolving Fund: quality vaccines at low cost.
    EPI Newsl; 1997 Aug; 19(4):6-7. PubMed ID: 12348218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A scoping review of interventions for vaccine stock management in primary health-care facilities.
    Iwu CJ; Jaca A; Abdullahi LH; Ngcobo NJ; Wiysonge CS
    Hum Vaccin Immunother; 2019; 15(11):2666-2672. PubMed ID: 31116638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analytics for vaccine economics and pricing: insights and observations.
    Robbins MJ; Jacobson SH
    Expert Rev Vaccines; 2015 Apr; 14(4):605-16. PubMed ID: 25435003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of sustainability policies on sterilization services in Latin America.
    Haws J; Bakamjian L; Williams T; Lassner KJ
    Stud Fam Plann; 1992; 23(2):85-96. PubMed ID: 1604462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.
    Glassman A; Cañón O; Silverman R
    Value Health; 2016 Dec; 19(8):913-920. PubMed ID: 27987640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.
    Amimo F; Lambert B; Magit A; Hashizume M
    Global Health; 2021 Apr; 17(1):42. PubMed ID: 33832487
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.